Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia

详细信息    查看全文

• 作者：Mary R. Lee^a ; ^{leemary@mail.nih.gov" class="auth_mail" title="E-mail the corresponding author} ; Heidi J. Wehring^b ; Robert P. McMahon^b ; Fang Liu^b ; Jared Linthicum^b ; Joseph G. Verbalis^c ; Robert W. Buchanan^b ; Gregory P. Strauss^d ; Leah H. Rubin^e ; Deanna L. Kelly^b
• 关键词：Oxytocin ; Schizophrenia ; Negative symptoms ; Oxytocin levels ; Positive symptoms ; Intranasal
• 刊名：Schizophrenia Research
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：172
• 期：1-3
• 页码：165-168
• 全文大小：364 K

文摘

Several clinical studies have found an inverse relationship between clinical symptoms and peripheral oxytocin (OT) levels in people with schizophrenia. As oxytocin is a putative treatment for schizophrenia, the effect of repeated dosing of OT on OT levels, clinical symptoms and the relationship between the two is of interest. In a, randomized, double blind, parallel group 3 week study (N = 28) with daily administration of intranasal OT (20 IU twice daily) or placebo (PBO), we examined the effect of OT administration on the correlation between the change in peripheral OT levels and change in clinical symptoms in patients with schizophrenia. At baseline, there were no significant treatment group differences in OT levels. There were no significant associations between baseline OT levels and any symptom measures. After 3 weeks of OT/PBO dosing, there was no significant difference in the magnitude of change in OT levels between the two treatment groups. Correlations between changes in peripheral OT levels and changes in the BPRS total and negative symptom scores were not different between treatment groups. Larger studies are needed to examine the effect of exogenous OT on peripheral OT levels and the relationship between the latter and clinical symptoms.

Clinical Trials.gov = NCT00884897.